JP2009502922A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009502922A5 JP2009502922A5 JP2008523976A JP2008523976A JP2009502922A5 JP 2009502922 A5 JP2009502922 A5 JP 2009502922A5 JP 2008523976 A JP2008523976 A JP 2008523976A JP 2008523976 A JP2008523976 A JP 2008523976A JP 2009502922 A5 JP2009502922 A5 JP 2009502922A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- membered
- disease
- aryl
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 37
- 150000001875 compounds Chemical class 0.000 claims 29
- 125000003118 aryl group Chemical group 0.000 claims 19
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 229910052799 carbon Inorganic materials 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 9
- 125000002723 alicyclic group Chemical group 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 125000001931 aliphatic group Chemical group 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 125000004429 atom Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- -1 1,2-methylenedioxy Chemical group 0.000 claims 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 5
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical group FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 claims 4
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 125000004641 (C1-C12) haloalkyl group Chemical group 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 claims 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 229940123169 Caspase inhibitor Drugs 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 claims 2
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims 1
- ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical compound C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 claims 1
- XEYKWYIXHMEQGM-UHFFFAOYSA-N 1,2-dihydro-1,8-naphthyridine Chemical compound C1=CC=C2C=CCNC2=N1 XEYKWYIXHMEQGM-UHFFFAOYSA-N 0.000 claims 1
- UXJHQQLYKUVLIE-UHFFFAOYSA-N 1,2-dihydroacridine Chemical compound C1=CC=C2N=C(C=CCC3)C3=CC2=C1 UXJHQQLYKUVLIE-UHFFFAOYSA-N 0.000 claims 1
- QRDNXAYNXUKMOO-UHFFFAOYSA-N 1,2-dihydrocinnoline Chemical compound C1=CC=C2C=CNNC2=C1 QRDNXAYNXUKMOO-UHFFFAOYSA-N 0.000 claims 1
- ZIZMDHZLHJBNSQ-UHFFFAOYSA-N 1,2-dihydrophenazine Chemical compound C1=CC=C2N=C(C=CCC3)C3=NC2=C1 ZIZMDHZLHJBNSQ-UHFFFAOYSA-N 0.000 claims 1
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical compound C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 claims 1
- XXBQLHATYQHJQC-UHFFFAOYSA-N 1,2-dihydroquinoxaline Chemical compound C1=CC=C2N=CCNC2=C1 XXBQLHATYQHJQC-UHFFFAOYSA-N 0.000 claims 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 claims 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 claims 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 claims 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 claims 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 claims 1
- YQQRKUQVFWYEPV-UHFFFAOYSA-N 5,6-dihydrophenanthridine Chemical compound C1=CC=C2CNC3=CC=CC=C3C2=C1 YQQRKUQVFWYEPV-UHFFFAOYSA-N 0.000 claims 1
- LDBZRFQWKQUHFF-UHFFFAOYSA-N 5h-pyridazino[4,5-b]indole Chemical compound N1=NC=C2C3=CC=CC=C3NC2=C1 LDBZRFQWKQUHFF-UHFFFAOYSA-N 0.000 claims 1
- PHHUQAFGPIDWPU-UHFFFAOYSA-N 5h-pyrrolo[3,2-c:4,5-c']dipyridine Chemical compound N1C2=CC=NC=C2C2=C1C=CN=C2 PHHUQAFGPIDWPU-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- 208000011594 Autoinflammatory disease Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 claims 1
- 102000011727 Caspases Human genes 0.000 claims 1
- 108010076667 Caspases Proteins 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000026292 Cystic Kidney disease Diseases 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims 1
- 206010053776 Eosinophilic cellulitis Diseases 0.000 claims 1
- 206010059284 Epidermal necrosis Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
- 208000035690 Familial cold urticaria Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 241000590002 Helicobacter pylori Species 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 206010019773 Hepatitis G Diseases 0.000 claims 1
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 1
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102100039898 Interleukin-18 Human genes 0.000 claims 1
- 201000005807 Japanese encephalitis Diseases 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000027747 Kennedy disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 206010038423 Renal cyst Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 206010043781 Thyroiditis chronic Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000008526 Wells syndrome Diseases 0.000 claims 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 1
- 208000003152 Yellow Fever Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000005000 autoimmune gastritis Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims 1
- 239000010836 blood and blood product Substances 0.000 claims 1
- 229940125691 blood product Drugs 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 208000001848 dysentery Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 208000028329 epileptic seizure Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 229940037467 helicobacter pylori Drugs 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 208000025487 periodic fever syndrome Diseases 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 229950000688 phenothiazine Drugs 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 claims 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 claims 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 claims 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 claims 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 0 CCC(CC1C2)=C(C)OC1(*)OC2=O Chemical compound CCC(CC1C2)=C(C)OC1(*)OC2=O 0.000 description 32
- QTZSTJGSJHRWSU-UHFFFAOYSA-N CC(C)COc(c(F)c(cc1F)F)c1F Chemical compound CC(C)COc(c(F)c(cc1F)F)c1F QTZSTJGSJHRWSU-UHFFFAOYSA-N 0.000 description 1
- PQCQMZPXWRQWHV-UHFFFAOYSA-N CC(C)COc1cc(C(F)(F)F)n[n]1C Chemical compound CC(C)COc1cc(C(F)(F)F)n[n]1C PQCQMZPXWRQWHV-UHFFFAOYSA-N 0.000 description 1
- VGANUOSTOZGOSY-UHFFFAOYSA-N CCSCc(cccc1)c1Cl Chemical compound CCSCc(cccc1)c1Cl VGANUOSTOZGOSY-UHFFFAOYSA-N 0.000 description 1
- YYROCZQCWNIJNV-UHFFFAOYSA-N CNC1NCCCC1 Chemical compound CNC1NCCCC1 YYROCZQCWNIJNV-UHFFFAOYSA-N 0.000 description 1
- XPCYMUBTCGGWOH-UHFFFAOYSA-N Cc1cncnc1C Chemical compound Cc1cncnc1C XPCYMUBTCGGWOH-UHFFFAOYSA-N 0.000 description 1
- FZESPVBONPPRAW-UHFFFAOYSA-N Cc1nc2cccnc2[nH]1 Chemical compound Cc1nc2cccnc2[nH]1 FZESPVBONPPRAW-UHFFFAOYSA-N 0.000 description 1
- JWQVOMJORQXNME-UHFFFAOYSA-N Cc1nc2cnccc2[nH]1 Chemical compound Cc1nc2cnccc2[nH]1 JWQVOMJORQXNME-UHFFFAOYSA-N 0.000 description 1
- PRYHHUQPRATBCZ-UHFFFAOYSA-N Cc1ncc(-c(c(Cl)ccc2)c2Cl)[o]1 Chemical compound Cc1ncc(-c(c(Cl)ccc2)c2Cl)[o]1 PRYHHUQPRATBCZ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70337505P | 2005-07-28 | 2005-07-28 | |
| PCT/US2006/028174 WO2007015931A2 (en) | 2005-07-28 | 2006-07-20 | Caspase inhibitor prodrugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009502922A JP2009502922A (ja) | 2009-01-29 |
| JP2009502922A5 true JP2009502922A5 (https=) | 2009-09-03 |
Family
ID=37709070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008523976A Pending JP2009502922A (ja) | 2005-07-28 | 2006-07-20 | カスパーゼ阻害剤プロドラッグ |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7879891B2 (https=) |
| EP (1) | EP1910379B1 (https=) |
| JP (1) | JP2009502922A (https=) |
| KR (1) | KR20080038369A (https=) |
| CN (1) | CN101268084A (https=) |
| AT (1) | ATE529430T1 (https=) |
| AU (1) | AU2006276096A1 (https=) |
| CA (1) | CA2616337A1 (https=) |
| IL (1) | IL188997A0 (https=) |
| NO (1) | NO20081050L (https=) |
| NZ (1) | NZ566022A (https=) |
| RU (1) | RU2427582C2 (https=) |
| WO (1) | WO2007015931A2 (https=) |
| ZA (1) | ZA200801172B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20050159A1 (es) | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
| MXPA06013256A (es) * | 2004-05-15 | 2007-02-08 | Vertex Pharma | Tratamiento de crisis convulsivas utilizando inhibidores ice. |
| ATE543803T1 (de) * | 2004-11-24 | 2012-02-15 | Vertex Pharma | 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren |
| EP1954277B1 (en) | 2005-11-03 | 2017-01-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| KR20090099886A (ko) * | 2008-03-18 | 2009-09-23 | 주식회사 엘지생명과학 | 캐스파제 저해제의 프로드럭 |
| WO2010017408A1 (en) | 2008-08-06 | 2010-02-11 | The Buck Institute For Age Research | Caspase inhibitors and uses thereof |
| SG176100A1 (en) * | 2009-05-22 | 2011-12-29 | Abbott Lab | Modulators of 5-ht receptors and methods of use thereof |
| ES2530266T3 (es) * | 2009-07-31 | 2015-02-27 | Global Alliance For Tb Drug Development | Análogos de nitroimidazooxazina y sus usos |
| WO2011014774A1 (en) * | 2009-07-31 | 2011-02-03 | Global Alliance For Tb Drug Development | Nitroimidazooxazines and their uses in anti-tubercular therapy |
| KR101770979B1 (ko) | 2010-05-21 | 2017-08-24 | 애브비 인코포레이티드 | 5ｈｔ 수용체의 조절제 및 이의 사용방법 |
| CN101979403A (zh) * | 2010-09-13 | 2011-02-23 | 沈陵陵 | 新型半胱氨酸天冬氨酸广谱蛋白酶抑制剂及其制备方法和用途 |
| US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
| US20180065990A1 (en) * | 2016-09-07 | 2018-03-08 | Dsm Ip Assets B.V. | Process for the preparation of a substituted imidazothiazolone compound |
| JP2022529973A (ja) * | 2019-04-19 | 2022-06-27 | エルジー・ケム・リミテッド | カスパーゼ阻害剤のプロドラッグ |
| WO2020222541A1 (ko) | 2019-04-30 | 2020-11-05 | 주식회사 엘지화학 | 캐스파제 저해제의 프로드럭 |
| EP3970698A4 (en) | 2019-05-31 | 2022-08-31 | LG Chem, Ltd. | INJECTABLE COMPOSITION WITH PRODRUG OF CASPASE INHIBITORS AND METHOD OF MANUFACTURE THEREOF |
| EP3970699A4 (en) | 2019-05-31 | 2022-08-10 | LG Chem, Ltd. | COMPOSITION FOR CASPASE INHIBITOR PRODRUG INJECTION |
| KR102670554B1 (ko) | 2022-01-04 | 2024-05-30 | 주식회사 이노보테라퓨틱스 | 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물 |
| WO2025221068A1 (ko) * | 2024-04-19 | 2025-10-23 | (주)노보메디슨 | 심장질환의 예방 또는 치료를 위한 캐스파제 저해제 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874424A (en) | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| SU1441748A1 (ru) * | 1987-03-04 | 1995-09-10 | Пермский государственный университет | 3-(4-бромфенил)-3а,4,6,6а-тетрагидрофуро[3,4-d]изоксазол-4-он, проявляющий противовоспалительную активность |
| SU1586154A1 (ru) * | 1988-09-15 | 2006-12-20 | Краснодарский политехнический институт | 3-(2,4-Дихлорфенил)-4-оксо-3a,4,6,6a-тетрагидрофуро-[3,4-d]изоксазол, проявляющий антигельминтную и анальгетическую активность |
| US5756466A (en) | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5847135A (en) | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US5716929A (en) | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| HU221138B1 (en) * | 1994-08-30 | 2002-08-28 | Sankyo Co | Condensed isoxazolyloxy- and -thioalkylamine derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| US5672584A (en) * | 1995-04-25 | 1997-09-30 | The University Of Kansas | Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability |
| US5843904A (en) | 1995-12-20 | 1998-12-01 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1βconverting enzyme |
| EP0929311B8 (en) | 1996-09-12 | 2006-02-01 | Idun Pharmaceuticals, Inc. | INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS |
| NZ330451A (https=) | 1996-09-12 | 2000-01-28 | Idun Pharmaceuticals Inc | |
| KR20000036056A (ko) | 1996-09-12 | 2000-06-26 | 아이디유엔 파마슈티칼즈, 인코포레이티드 | 인터루킨-1β 전환 효소 및 관련 프로테아제의 억제제로서의 Ｃ-말단 변형된 (Ｎ-치환된)-2-인돌릴 디펩티드 |
| US5968927A (en) * | 1996-09-20 | 1999-10-19 | Idun Pharmaceuticals, Inc. | Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes |
| WO1998016502A1 (en) | 1996-10-11 | 1998-04-23 | Warner-Lambert Company | ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME |
| US5919790A (en) | 1996-10-11 | 1999-07-06 | Warner-Lambert Company | Hydroxamate inhibitors of interleukin-1β converting enzyme |
| US6184244B1 (en) * | 1996-12-16 | 2001-02-06 | Idun Pharmaceuticals, Inc. | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US6184210B1 (en) * | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
| JP2002509153A (ja) | 1998-01-20 | 2002-03-26 | ワーナー−ランバート・カンパニー | インターロイキン−１β変換酵素（ＩＣＥ）のインビボ阻害剤としてのＮ−［２−（５−ベンジルオキシカルボニル−アミノ−６−オキソ−２−（４−フルオロフェニル）−１，６−ジヒドロ−１−ピリミジニル）アセトキシル］−Ｌ−アスパラギン酸アルデヒド |
| DE69925581T2 (de) * | 1998-03-09 | 2006-04-27 | Vertex Pharmaceuticals Inc., Cambridge | 1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms |
| DK1064298T3 (da) * | 1998-03-19 | 2009-01-19 | Vertex Pharma | Inhibitorer af caspaser |
| US6197750B1 (en) * | 1998-07-02 | 2001-03-06 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US6242422B1 (en) * | 1998-10-22 | 2001-06-05 | Idun Pharmacueticals, Inc. | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| ES2274795T3 (es) | 1999-07-19 | 2007-06-01 | Merck Frosst Canada Ltd. | Pirazinonas, composiciones que contienen tales compuestos. |
| EP1163208B1 (en) * | 1999-08-06 | 2004-05-12 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| AR026748A1 (es) * | 1999-12-08 | 2003-02-26 | Vertex Pharma | Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis |
| PE20011267A1 (es) * | 2000-03-29 | 2001-12-15 | Vertex Pharma | Carbamato como inhibidores de caspasa |
| CA2402128A1 (en) * | 2000-04-24 | 2001-11-01 | Vertex Pharmaceuticals Incorporated | Process and intermediates for making substituted aspartic acid acetals |
| PE20011350A1 (es) * | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
| TR200200767T1 (tr) * | 2000-05-23 | 2002-09-23 | Vertex Pharmaceuticals Incorporated | Kaspaz engelleyiciler ve kullanımları |
| EP1289993B9 (en) * | 2000-06-07 | 2008-08-20 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| WO2002022611A2 (en) * | 2000-09-13 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| AU2002232541A1 (en) * | 2000-11-21 | 2002-06-03 | Vertex Pharmaceuticals Incorporated | Imidazole and benzimidazole caspase inhibitors and uses thereof |
| US20030096737A1 (en) | 2001-04-19 | 2003-05-22 | Anita Diu-Hercend | Caspase inhibitors and uses thereof |
| JP4428926B2 (ja) * | 2001-05-23 | 2010-03-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | カスパーゼインヒビターおよびそれらの使用 |
| PE20040728A1 (es) * | 2002-06-28 | 2004-10-23 | Vertex Pharma | Inhibidores de caspasa |
| PE20050159A1 (es) * | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
-
2006
- 2006-07-20 KR KR1020087004718A patent/KR20080038369A/ko not_active Ceased
- 2006-07-20 CN CNA2006800345091A patent/CN101268084A/zh active Pending
- 2006-07-20 ZA ZA200801172A patent/ZA200801172B/xx unknown
- 2006-07-20 NZ NZ566022A patent/NZ566022A/en not_active IP Right Cessation
- 2006-07-20 WO PCT/US2006/028174 patent/WO2007015931A2/en not_active Ceased
- 2006-07-20 US US11/489,939 patent/US7879891B2/en not_active Expired - Fee Related
- 2006-07-20 RU RU2008107576/04A patent/RU2427582C2/ru not_active IP Right Cessation
- 2006-07-20 EP EP06787963A patent/EP1910379B1/en not_active Not-in-force
- 2006-07-20 AU AU2006276096A patent/AU2006276096A1/en not_active Abandoned
- 2006-07-20 AT AT06787963T patent/ATE529430T1/de not_active IP Right Cessation
- 2006-07-20 JP JP2008523976A patent/JP2009502922A/ja active Pending
- 2006-07-20 CA CA002616337A patent/CA2616337A1/en not_active Abandoned
-
2008
- 2008-01-24 IL IL188997A patent/IL188997A0/en not_active IP Right Cessation
- 2008-02-28 NO NO20081050A patent/NO20081050L/no not_active Application Discontinuation
-
2010
- 2010-12-17 US US12/971,649 patent/US8168798B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009502922A5 (https=) | ||
| CA3081790C (en) | Macrocyclic compounds as trk kinase inhibitors and uses thereof | |
| RU2008107576A (ru) | Пролекарства ингибитора каспазы | |
| KR102714478B1 (ko) | 치환된 다환성 피리돈 유도체의 입체 선택적인 제조 방법 | |
| TW202309025A (zh) | Parp1抑制劑及其用途 | |
| CA2856886C (fr) | Nouveaux derives phosphates, leur utilisation en cancerologie, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| CA3174837A1 (en) | Pyrazolo[1,5-d][1,2,4]triazine-5(4h)-acetamides as inhibitors of the nlrp3 inflammasome pathway | |
| TW202425982A (zh) | 泛素特異性蛋白酶1的抑制劑及其應用 | |
| KR102519536B1 (ko) | 트리시클릭 회전장애이성질체 화합물 | |
| EA023824B1 (ru) | ПРОИЗВОДНЫЕ 3,4-ДИГИДРОПИРРОЛО[1,2-a]ПИРАЗИН-1-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE) | |
| JP2005505618A5 (https=) | ||
| JP2005533825A5 (https=) | ||
| EP3024833A1 (fr) | Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| CA2447999A1 (en) | Caspase inhibitors and uses thereof | |
| CN116406363A (zh) | 四环类衍生物、其制备方法及其医药上的用途 | |
| PT1666477E (pt) | Derivado de 7-(4-substituído-3-ciclopropilaminometil-1- pirrolidinil) quinolonecarboxílico | |
| JP6513075B2 (ja) | オートタキシン阻害活性を有する縮合ピラゾール誘導体 | |
| EP2757883A1 (en) | Triazolopyridyl compounds as aldosterone synthase inhibitors | |
| JP2024523646A (ja) | ５－オキソ－ピリド［２，３－ｄ］ピリダジン－６（５Ｈ）－イルアセトアミド | |
| ES2286408T3 (es) | Sales de alquilamonio de omeprazol e esomeprazol. | |
| RU2709810C2 (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛО[3,4-с]ПИРИДИНА | |
| JP2007525503A5 (https=) | ||
| RU2006134258A (ru) | Ингибиторы каспаз и их применение | |
| JP2022549345A (ja) | マイコバクテリア感染症の処置のためのアザインドールカルボキサミド化合物 | |
| ES2371171A1 (es) | Derivados de camptotecina como agentes antitumorales. |